206 related articles for article (PubMed ID: 31924231)
1. Immunological features of patients affected by Barraquer-Simons syndrome.
Corvillo F; Ceccarini G; Nozal P; Magno S; Pelosini C; Garrido S; López-Lera A; Moraru M; Vilches C; Fornaciari S; Gabbriellini S; Santini F; Araújo-Vilar D; López-Trascasa M
Orphanet J Rare Dis; 2020 Jan; 15(1):9. PubMed ID: 31924231
[TBL] [Abstract][Full Text] [Related]
2. Evidence of ongoing complement activation on adipose tissue from an 11-year-old girl with Barraquer-Simons syndrome.
Corvillo F; Nozal P; López-Lera A; De Miguel MP; Piñero-Fernández JA; De Lucas R; García-Concepción MD; Beato MJ; Araújo-Vilar D; López-Trascasa M
J Dermatol; 2020 Dec; 47(12):1439-1444. PubMed ID: 32890433
[TBL] [Abstract][Full Text] [Related]
3. Acquired partial lipodystrophy and C3 glomerulopathy: Dysregulation of the complement system as a common pathogenic mechanism.
Corvillo F; López-Trascasa M
Nefrologia (Engl Ed); 2018; 38(3):258-266. PubMed ID: 29279276
[TBL] [Abstract][Full Text] [Related]
4. Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer-Simons syndrome).
Corvillo F; González-Sánchez L; López-Lera A; Arjona E; Ceccarini G; Santini F; Araújo-Vilar D; Brown RJ; Villarroya J; Villarroya F; Rodríguez de Córdoba S; Caballero T; Nozal P; López-Trascasa M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205507
[TBL] [Abstract][Full Text] [Related]
5. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics of Patients With Acquired Partial Lipodystrophy: A Multicenter Retrospective Study.
Magno S; Ceccarini G; Corvillo F; Pelosini C; Gilio D; Paoli M; Fornaciari S; Pandolfo G; Sanchez-Iglesias S; Nozal P; Curcio M; Sessa MR; López-Trascasa M; Araújo-Vilar D; Santini F
J Clin Endocrinol Metab; 2024 Feb; 109(3):e932-e944. PubMed ID: 38061004
[TBL] [Abstract][Full Text] [Related]
7. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
Habib R; Lévy M; Gubler MC; Broyer M; Habib M
Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
[TBL] [Abstract][Full Text] [Related]
8. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
9. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
10. [Barraquer-Simons syndrome in a patient with systemic lupus erythematosus].
Ben Ghorbel I; Ben Salem T; Lamloum M; Braham A; Khanfir M; Miled M; Houman MH
Rev Med Interne; 2010 May; 31(5):372-4. PubMed ID: 20399545
[TBL] [Abstract][Full Text] [Related]
11. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
Levy Y; George J; Yona E; Shoenfeld Y
Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
[TBL] [Abstract][Full Text] [Related]
12. Loss of autoantibody activity by alteration in autoantigen.
Spitzer RE; Stitzel AE
Clin Immunol Immunopathol; 1996 Aug; 80(2):211-3. PubMed ID: 8764567
[TBL] [Abstract][Full Text] [Related]
13. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
14. [Barraquer and Simons lipodystrophy. Complement anomalies and cutaneous leukocytoclasic vasculitis].
Perrot H; Delaup JP; Chouvet B
Ann Dermatol Venereol; 1987; 114(9):1083-91. PubMed ID: 3434945
[TBL] [Abstract][Full Text] [Related]
15. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
16. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
17. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
Front Immunol; 2019; 10():886. PubMed ID: 31068950
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
19. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).
Ohi H; Yasugi T
Clin Exp Immunol; 1994 Feb; 95(2):316-21. PubMed ID: 8306508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
